NCT07140315View on ClinicalTrials.gov

DK222 Study at Hopkins

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

February 1, 2027

Conditions
Non-Small Cell Lung CancerUrothelial Cancer
Interventions
DRUG

[18F]DK222 radiotracer

\[18F\]DK222 is an investigational radiotracer used detect non-small cell lung cancer (NSCLC) or Urothelial Cancer (UC) tissue in the body when used with positron emission tomography/computed tomography. Participants will undergo a PET-CT scan after \[18F\]DK222 is injected into the participant's vein an intravenous line.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER